Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 12/10/14  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Siggi O. Olafsson

Wrong Siggi O. Olafsson?

President and Chief Executive Off...

Teva Pharmaceutical Industries Ltd.
1090 Horsham Rd.
North Wales , Pennsylvania 19454
United States

Company Description: Teva Pharmaceutical Industries Ltd. is a pharmaceutical company that develops, produces and markets generic drugs covering all major treatment categories. The...   more
Background

Employment History

  • President and Chief Executive Officer of Global Generic Medicines
    Teva Pharmaceutical Industries Ltd.
  • President
    Actavis Ltd
  • Chief Executive Officer
    Actavis Ltd
  • Executive Vice President
    Actavis Ltd
  • Executive Vice President
    Watson
  • President of Global Generics Business
    Watson
  • Executive Vice President
    Global Generics
  • President
    Global Generics
  • Watson's President
    Global Generics
  • Responsible Positions
    Pfizer Inc
  • Head of Drug Development
    Omega Farma

Education

  • M.S. , Pharmacy
    University of Iceland
13 Total References
Web References
The addition of Celecoxib Capsules to ...
www.drugstorenews.com, 10 Dec 2014 [cached]
The addition of Celecoxib Capsules to our U.S. generics portfolio is further evidence of Teva's commitment to bring affordable treatment solutions to patients," said Siggi Olafsson, president and CEO of global generic medicines at Teva.
Siggi O. Olafsson was ...
actavis.com, 26 Oct 2013 [cached]
Siggi O. Olafsson was appointed President, of Watson's Global Generics business on April 27, 2012. Following the completion of the Actavis acquisition, the division was renamed Actavis Pharma. He joined Watson as Executive Vice President, Global Generics in September 2010. Prior to joining Watson, Mr. Olafsson served as CEO of Actavis Group, where he was responsible for overseeing Actavis' global pharmaceutical business with operations in more than 40 countries. From 2006 to 2008, Mr. Olafsson served as Deputy CEO of Actavis Group, and was CEO, Actavis Inc. U.S. and Chief Executive Corporate Development from 2003-2006, where he led Actavis U.S. sales and marketing organization, and also led the acquisition and integration of Pharma Avalanche, Biovena, Lotus Laboratories, Amide Pharmaceuticals and Alpharma Generics. Prior to joining Actavis, Mr. Olafsson held increasingly responsible positions with Pfizer's Global Research and Development organization in both the U.S. and in the U.K. from 1998 until 2003. Prior to joining Pfizer, he served as head of Drug Development for Omega Farma in Iceland for four years. Mr. Olafsson has a M.S. in Pharmacy (Cand Pharm) from the University of Iceland.
"The acquisition of these products will ...
www.pharmpro.com, 18 April 2014 [cached]
"The acquisition of these products will complement our expanding portfolio of topical and ophthalmic generic products, and further strengthen our position as a leader in developing and marketing the complex, high-barrier products that provide enhanced value," said Siggi Olafsson, President, Actavis Pharma.
Siggi O. Olafsson joins ...
ir.actavis.com, 10 Feb 2013 [cached]
Siggi O. Olafsson joins the Actavis plc Board of Directors effective following the closing of the Warner Chilcott acquisition. Mr. Olafsson is the President of Actavis Pharma - Actavis' generic, branded generic, legacy brands and over-the-counter business. He joined the Company as Executive Vice President, Global Generics in September 2010 , and was appointed President of the Global Generics business in April 2012. Prior to joining the Company, Mr. Olafsson served as CEO of the
...
, Mr. Olafsson held increasingly responsible positions with Pfizer's
...
Mr. Olafsson has a M.S. in Pharmacy (Cand Pharm) from the
Siggi O. Olafsson joins the ...
www.biospace.com, 2 Oct 2013 [cached]
Siggi O. Olafsson joins the Actavis plc Board of Directors effective following the closing of the Warner Chilcott acquisition. Mr. Olafsson is the President of Actavis Pharma Actavis' generic, branded generic, legacy brands and over-the-counter business. He joined the Company as Executive Vice President, Global Generics in September 2010, and was appointed President of the Global Generics business in April 2012. Prior to joining the Company, Mr. Olafsson served as CEO of the Actavis Group (the legacy Actavis business acquired by the Company in 2012), where he was responsible for overseeing the Company's global pharmaceutical business with operations in more than 40 countries. Prior to joining the Actavis Group, Mr. Olafsson held increasingly responsible positions with Pfizer's Global Research and Development organization in both the U.S. and the UK from 1998 until 2003, and served as head of Drug Development for Omega Farma in Iceland for four years. Mr. Olafsson has a M.S. in Pharmacy (Cand Pharm) from the University of Iceland.
Other People with the name "Olafsson":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304